ArticleAntimicrobial agents and chemotherapy2022
Gene Amplification of
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Pooled it
- Mapping the Global Spread of T. indotineae: An Update on Antifungal Resistance, Mutations, and Strategies for Effective Management.Mycopathologia · 2024Pooled it
- Deciphering the genomic landscape ofMicrobial genomics · 2026Article
- Trichophyton indotineae: Rise, Diagnosis, Treatment, and Future Directions.American journal of clinical dermatology · 2026Review
- Resistance and Recalcitrance in Dermatophytosis: Mechanistic and Clinical Considerations for Keratinized Tissues.Antibiotics (Basel, Switzerland) · 2026Review
- The emergence of superficial dermatophytosis due toJournal of clinical microbiology · 2026Article
- A Study on the Species Diversity, Mating Types, and Clinical Relevance of Trichophyton mentagrophytes/interdigitale Complex Infections in Guizhou Province.Mycopathologia · 2026Article
- The entireAntimicrobial agents and chemotherapy · 2026Article
- Article
- Rising antifungal resistance inFrontiers in microbiology · 2026Review
- Emerging antifungal resistance inEmerging microbes & infections · 2025Article
- Recalcitrant dermatophytosis due toMedical mycology case reports · 2025Article
- Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multipleAntimicrobial agents and chemotherapy · 2025Article
- The First Isolation of Multiple Antifungal-Drug-Resistant Trichophyton Rubrum in China and the Novel Resistance Mechanism.Mycoses · 2025Article
- Co-Treatment with Ritonavir or Sertraline Enhances Itraconazole Efficacy Against Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Article
- National Belgian Study on Terbinafine Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- [Development of resistance in skin fungi : Molecular mechanisms, antifungal resistance assays, risk factors, and diagnostic regime-challenges for medical treatment].Dermatologie (Heidelberg, Germany) · 2025Review
- Evolution of antifungal resistance in the environment.Nature microbiology · 2025Review
- Significant Impact of Growth Medium on Itraconazole Susceptibility in Azole-Resistant Versus Wild-TypeInternational journal of molecular sciences · 2025Article
- Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte,Journal of clinical microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trichophyton indotineae causes dermatophytosis that is resistant to terbinafine and azole compounds. The aim of this study was to determine the mechanisms of resistance to itraconazole (ITC) and voriconazole (VRC) in strains of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.